CAS 1048668-70-7

AZD8329

Description:

AZD8329 is a small molecule inhibitor primarily developed for therapeutic applications in oncology, particularly targeting specific pathways involved in cancer cell proliferation and survival. It is designed to inhibit certain kinases, which play a crucial role in signaling pathways that regulate cell growth and division. The compound exhibits characteristics typical of targeted cancer therapies, including selectivity for its molecular targets, which helps minimize off-target effects and improve efficacy. AZD8329 is often evaluated in preclinical and clinical studies to assess its pharmacokinetics, bioavailability, and safety profile. Its chemical structure includes functional groups that contribute to its binding affinity and specificity for the intended targets. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, potential resistance mechanisms, and optimal therapeutic combinations. Overall, AZD8329 represents a promising candidate in the field of targeted cancer therapy, reflecting the ongoing efforts to develop more effective and personalized treatment options for patients.

AZD8329

CAS: 1048668-70-7

AZD8329

Purity: ≥98%

Molecular weight: 421.53g/mol

Ref: 54-BUP04819

AZD 8329

CAS: 1048668-70-7

AZD 8329 is an orally active, small-molecule inhibitor of the enzyme fatty acid synthase (FAS) that has been shown to be safe and well tolerated in clinical trials. It is currently being studied as a potential treatment for obesity, type 2 diabetes mellitus, and other metabolic disorders. AZD 8329 has a novel mechanism of action that blocks the synthesis of fatty acids, which are a major energy source in the body. This drug also inhibits adipose tissue lipolysis and suppresses appetite. The drug's effects on insulin sensitivity have not been fully elucidated, but it may represent an alternative to thiazolidinediones such as rosiglitazone because it does not appear to increase cardiovascular risk or cause edema. AZD 8329 was found to inhibit FAS activity by competitive inhibition with microglial activation in vitro with up to 95% inhibition at concentrations of 10 μM. In vivo studies demonstrated that AZD 8329 effectively reduced

Formula: C₂₅H₃₁N₃O₃

Purity: Min. 95%

Molecular weight: 421.5 g/mol

Ref: 3D-BA179810

AZD8329

CAS: 1048668-70-7

AZD8329 is an 11β-HSD1 inhibitor that inhibits 11β-HSD2, 17β-HSD1, 17β-HSD3, and can be used to study allergic reactions in humans.

Formula: C₂₅H₃₁N₃O₃

Purity: 99.31%

Color and Shape: Solid

Molecular weight: 421.53

Ref: TM-T14383